Replies to post #1293 on Synaptogenix Inc (SNPX)

[F1ash]

---------
"Has this drug, this trial, this research been scrutinized yet by the greater scientific community? Has Neurotrope presented their findings anywhere besides conferences for investors? Have their findings been pulbished in any peer reviewed journals? What was the response by the scientific community? Crickets? Have any independent, 3rd party scientists commented on bryostatin's chances to cure Alzheimers, or anything else?"
------------/--


Gee I don't know, would the cover of "The Journal of Biological Chemistry" count?

"On The Cover: Integrative neurons in the hippocampus show large oval nuclei (blue) and presynaptic axonal boutons. Yellow grains, boutons with brain-derived neurotrophic factor (BDNF); green grains, boutons with no BDNF accumulation; red grains, postsynaptic dendritic spines with BDNF. BDNF is important for synaptic activity and neuron survival. The PKCe activator, bryostatin 1, enhanced the presence of the synaptogenic growth factor, BDNF, as indicated by the yellow dots. For details, see the JBC article by Sen et al., pages 16462–16476."

Dr Alkon has over 300 pier reviewed publications.... that enough for you? How many does Missling have?

http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/HomePage-Forms/Neurotrope%20%20100516.pdf


What would you like them to do, run around trumpeting "efficacy" from an underpowered unblinded non- placebo controlled 2a study. Maybe if this trial proves the promise of the drug they will "make the rounds".

[Theburg]

Just about all of the failed AD drugs would have answered yes to those questions. So what does that tell you?